Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-negative Breast Cancer|Metastatic Breast Cancer|Triple Negative Breast Cancer
Interventions: DRUG: Olaparib
Sponsor: SOLTI Breast Cancer Research Group